Abstract
The pathogenesis of Alzheimers disease (AD) involves the abnormal accumulation and deposition of β- amyloid in cerebral blood vessels and in the brain parenchyma. Critical in modulating β-amyloid deposition in brain is the flux of Aβ across the blood brain barrier. The low-density lipoprotein receptor-related protein (LRP), is a large endocytic receptor that mediates the efflux of Aβ out of brain and into the periphery. The first step in the LRP-mediated clearance of Ab involves the formation of a complex between Aβ and the LRP ligands apolipoprotein E (apoE) or α2-macroglobulin (α2M). The Aβ / chaperone complexes then bind to LRP via binding sites on apoE or α2M. The efflux of Aβ / chaperone complexes out of the neuropil and into the periphery may be attenuated by LRP-ligands that compete with apoE or α2M for LRP binding. LRP is also the cell surface receptor for Kunitz Protease Inhibitor (KPI) containing isoforms of Abs parent protein, the amyloid protein precursor (APP). Protein and mRNA levels of KPI-containing APP isoforms (APP-KPI) are elevated in AD brain and are associated with increased Ab production. In this study we show that soluble non-amyloidogenic APP-KPI can also inhibit the uptake of Aβ / α2M in a cell culture model of LRP mediated Aβ clearance. Clearance of Aβ / apoE complexes was not inhibited by APP-KPI. Our findings are consistent with studies showing that apoE and α2M have discrete binding sites on LRP. Most significantly, our data suggests that the elevated levels of APP-KPI in AD brain may attenuated the clearance of Aβ, the proteins own amyloidogenic catabolic product.
Keywords: alzheimers disease, clearance, low density lipoprotein receptor-related protein, apolipoprotein e, macroglobulin, amyloid protein precursor
Current Alzheimer Research
Title: LRP-Mediated Clearance of Aβ is Inhibited by KPI-Containing Isoforms of APP
Volume: 2 Issue: 2
Author(s): Robert D. Moir and Rudolph E. Tanzi
Affiliation:
Keywords: alzheimers disease, clearance, low density lipoprotein receptor-related protein, apolipoprotein e, macroglobulin, amyloid protein precursor
Abstract: The pathogenesis of Alzheimers disease (AD) involves the abnormal accumulation and deposition of β- amyloid in cerebral blood vessels and in the brain parenchyma. Critical in modulating β-amyloid deposition in brain is the flux of Aβ across the blood brain barrier. The low-density lipoprotein receptor-related protein (LRP), is a large endocytic receptor that mediates the efflux of Aβ out of brain and into the periphery. The first step in the LRP-mediated clearance of Ab involves the formation of a complex between Aβ and the LRP ligands apolipoprotein E (apoE) or α2-macroglobulin (α2M). The Aβ / chaperone complexes then bind to LRP via binding sites on apoE or α2M. The efflux of Aβ / chaperone complexes out of the neuropil and into the periphery may be attenuated by LRP-ligands that compete with apoE or α2M for LRP binding. LRP is also the cell surface receptor for Kunitz Protease Inhibitor (KPI) containing isoforms of Abs parent protein, the amyloid protein precursor (APP). Protein and mRNA levels of KPI-containing APP isoforms (APP-KPI) are elevated in AD brain and are associated with increased Ab production. In this study we show that soluble non-amyloidogenic APP-KPI can also inhibit the uptake of Aβ / α2M in a cell culture model of LRP mediated Aβ clearance. Clearance of Aβ / apoE complexes was not inhibited by APP-KPI. Our findings are consistent with studies showing that apoE and α2M have discrete binding sites on LRP. Most significantly, our data suggests that the elevated levels of APP-KPI in AD brain may attenuated the clearance of Aβ, the proteins own amyloidogenic catabolic product.
Export Options
About this article
Cite this article as:
Moir D. Robert and Tanzi E. Rudolph, LRP-Mediated Clearance of Aβ is Inhibited by KPI-Containing Isoforms of APP, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585918
DOI https://dx.doi.org/10.2174/1567205053585918 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volume 4
Cardiovascular & Hematological Agents in Medicinal Chemistry Quantitative Structure Activity Relationship Studies of Piperazinyl Phenylalanine Derivatives as VLA-4/VCAM-1 Inhibitors
Medicinal Chemistry Potential Applications for Using Stem Cells in Spine Surgery
Current Stem Cell Research & Therapy Synopsis of Expert Opinions and Conclusions
CNS & Neurological Disorders - Drug Targets Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets A Review on the Nutritional Aspects of Wild Edible Plants
Current Traditional Medicine Serotonin 5-HT<sub>4</sub> Receptors: A New Strategy for Developing Fast Acting Antidepressants?
Current Pharmaceutical Design Role of Flavonoids in Neurodegenerative Disorders with Special Emphasis on Tangeritin
CNS & Neurological Disorders - Drug Targets Brain Connectivity Networks in Schizophrenia Underlying Resting State Functional Magnetic Resonance Imaging
Current Topics in Medicinal Chemistry One-Pot Multi-Component Route to Propargylamines Using Zinc Oxide Under Solvent-Free Conditions
Combinatorial Chemistry & High Throughput Screening Neurofibrillary Tangles and Senile Plaques in Alzheimers Brains are Associated with Reduced Capillary Expression of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase
Current Neurovascular Research Single-chain Antibody Against Reg4 Suppresses Gastric Cancer Cell Growth and Enhances 5-FU-induced Cell Death in vitro
Anti-Cancer Agents in Medicinal Chemistry Sulforaphane Treatment of Young Men with Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease
Current Enzyme Inhibition Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin
Current Neuropharmacology Meet Our Editorial Board Member
Current Alzheimer Research MCI Patients Declining and Not-Declining at Mid-Term Follow-Up: FDG-PET Findings
Current Alzheimer Research Roles of Methionine Suldfoxide Reductases in Antioxidant Defense, Protein Regulation and Survival
Current Pharmaceutical Design Stability and Drug Metabolism Assessed by Electrochemical Methods
Combinatorial Chemistry & High Throughput Screening